Novel plasma biomarker surrogating cerebral amyloid deposition

Proceedings of the Japan Academy Series B: Physical and Biological Sciences

Volumn 90, Issue 9, 2014, Pages 353-364

  Kaneko, Naoki ^a   Nakamura, Akinori ^b   Washimi, Yukihiko ^b   Kato, Takashi ^b   Sakurai, Takashi ^b   Arahata, Yutaka ^b   Bundo, Masahiko ^b   Takeda, Akinori ^b   Niida, Shumpei ^b   Ito, Kengo ^b   Toba, Kenji ^b   Tanaka, Koichi ^a   Yanagisawa, Katsuhiko ^b  

^a SHIMADZU CORPORATION   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Alzheimer's disease; Amyloid protein; Biomarker; Immunoprecipitation; Mass spectrometry; PiB amyloid imaging

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; BLOOD; FEMALE; HUMAN; IMMUNOPRECIPITATION; MALE; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; FEMALE; HUMANS; IMMUNOPRECIPITATION; MAGNETIC RESONANCE IMAGING; MALE; MASS SPECTROMETRY; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84923873904     PISSN: 03862208     EISSN: 13492896     Source Type: Journal    
DOI: 10.2183/pjab.90.353     Document Type: Article

References (37)

1. Blennow, K., Zetterberg, H. and Fagan, A.M. (2012) Fluid biomarkers in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006221.
2. Henriksen, K., O'Bryant, S.E., Hampel, H., Trojanowski, J.Q., Montine, T.J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss-Coray, T., Soares, H., Bazenet, C., Sjögren, M., Hu, W., Lovestone, S., Karsdal, M.A., Weiner, M.W. and Group, B.-B. B. I. (2014) The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 10, 115-131.
3. Fagan, A.M., Mintun, M.A., Mach, R.H., Lee, S.Y., Dence, C.S., Shah, A.R., LaRossa, G.N., Spinner, M.L., Klunk, W.E., Mathis, C.A., DeKosky, S.T., Morris, J.C. and Holtzman, D.M. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59, 512-519.
4. Pike, K.E., Savage, G., Villemagne, V.L., Ng, S., Moss, S.A., Maruff, P., Mathis, C.A., Klunk, W.E., Masters, C.L. and Rowe, C.C. (2007) Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844.
5. Fagan, A.M., Head, D., Shah, A.R., Marcus, D., Mintun, M., Morris, J.C. and Holtzman, D.M. (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 65, 176-183.
6. Jack, C.R., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C. and Trojanowski, J.Q. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128.
7. Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M., Holtzman, D.M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P.S., Ghetti, B., Klunk, W.E., McDade, E., Martins, R.N., Masters, C.L., Mayeux, R., Ringman, J.M., Rossor, M.N., Schofield, P.R., Sperling, R.A., Salloway, S., Morris, J.C. and Network, D.I.A. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804.
8. Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., Szoeke, C., Macaulay, S.L., Martins, R., Maruff, P., Ames, D., Rowe, C.C. Masters, C.L. and Group, A. I. B. a. L. A. R. (2013) Amyloid O deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357-367.
9. Jack, C.R., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., Shaw, L.M., Vemuri, P., Wiste, H.J., Weigand, S.D., Lesnick, T.G., Pankratz, V.S., Donohue, M.C. and Trojanowski, J.Q. (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216.
10. Rissman, R.A., Trojanowski, J.Q., Shaw, L.M. and Aisen, P.S. (2012) Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J. Neural Transm. 119, 843-850.
11. Rembach, A., Faux, N.G., Watt, A.D., Pertile, K.K., Rumble, R.L., Trounson, B.O., Fowler, C.J., Roberts, B.R., Perez, K.A., Li, Q.X., Laws, S.M., Taddei, K., Rainey-Smith, S., Robertson, J.S., Vandijck, M., Vanderstichele, H., Barnham, K.J., Ellis, K.A., Szoeke, C., Macaulay, L., Rowe, C.C., Villemagne, V.L., Ames, D., Martins, R.N., Bush, A.I., Masters, C.L. and group, A. r. (2014) Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement. 10, 53-61.
12. Figurski, M.J., Waligórska, T., Toledo, J., Vanderstichele, H., Korecka, M., Lee, V.M., Trojanowski, J.Q., Shaw, L.M. and Initiative, A. s. D. N. (2012) Improved protocol for measurement of plasma O-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. Alzheimers Dement. 8, 250-260.
13. Song, F., Poljak, A., Valenzuela, M., Mayeux, R., Smythe, G.A. and Sachdev, P.S. (2011) Metaanalysis of plasma amyloid-O levels in Alzheimer's disease. J. Alzheimers Dis. 26, 365-375.
14. Toledo, J.B., Vanderstichele, H., Figurski, M., Aisen, P.S., Petersen, R.C., Weiner, M.W., Jack, C.R., Jagust, W., Decarli, C., Toga, A.W., Toledo, E., Xie, S.X., Lee, V.M., Trojanowski, J.Q., Shaw, L.M. and Initiative, A. s. D. N. (2011) Factors affecting AO plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 122, 401-413.
15. Toledo, J.B., Shaw, L.M. and Trojanowski, J.Q. (2013) Plasma amyloid beta measurements-a desired but elusive Alzheimer's disease biomarker. Alzheimers Res. Ther. 5, 8.
16. Kaneko, N., Yoshimori, T., Yamamoto, R., Capon, D.J., Shimada, T., Sato, T.A. and Tanaka, K. (2013) Multi epitope-targeting immunoprecipitation using F(abB) fragments with high affinity and specificity for the enhanced detection of a peptide with matrix-assisted laser desorption ionizationtime-of-flight mass spectrometry. Anal. Chem. 85, 3152-3159.
17. Kaneko, N., Yamamoto, R., Sato, T.A. and Tanaka, K. (2014) Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 90, 104-117.
18. De Meyer, G., Shapiro, F., Vanderstichele, H., Vanmechelen, E., Engelborghs, S., De Deyn, P.P., Coart, E., Hansson, O., Minthon, L., Zetterberg, H., Blennow, K., Shaw, L., Trojanowski, J.Q. and Initiative, A. s. D. N. (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 67, 949-956.
19. Snowdon, D.A. (1997) Aging and Alzheimer's disease: lessons from the Nun Study. Gerontologist 37, 150-156.
20. Price, J.L. and Morris, J.C. (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 45, 358-368.
21. Davis, D.G., Schmitt, F.A., Wekstein, D.R. and Markesbery, W.R. (1999) Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 58, 376-388.
22. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S. and Phelps, C.H. (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263-269.
23. Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, P.J., Carrillo, M.C., Thies, B. and Phelps, C.H. (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270-279.
24. Rabinovici, G.D., Rosen, H.J., Alkalay, A., Kornak, J., Furst, A.J., Agarwal, N., Mormino, E.C., O'Neil, J.P., Janabi, M., Karydas, A., Growdon, M.E., Jang, J.Y., Huang, E.J., Dearmond, S.J., Trojanowski, J.Q., Grinberg, L.T., Gorno-Tempini, M.L., Seeley, W.W., Miller, B.L. and Jagust, W.J. (2011) Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 77, 2034-2042.
25. Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B. and Joliot, M. (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI singlesubject brain. Neuroimage 15, 273-289.
26. Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Korner, A., Minthon, L., Garraux, G., Nelissen, N., Bormans, G., Buckley, C., Owenius, R., Thurfjell, L., Farrar, G. and Brooks, D.J. (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 68, 319-329.
27. Irwin, D.J., McMillan, C.T., Toledo, J.B., Arnold, S.E., Shaw, L.M., Wang, L.S., Van Deerlin, V., Lee, V.M., Trojanowski, J.Q. and Grossman, M. (2012) Comparison of cerebrospinal fluid levels of tau and AO 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch. Neurol. 69, 1018-1025.
28. Jagust, W.J., Landau, S.M., Shaw, L.M., Trojanowski, J.Q., Koeppe, R.A., Reiman, E.M., Foster, N.L., Petersen, R.C., Weiner, M.W., Price, J.C., Mathis, C.A. and Initiative, A. s. D. N. (2009) Relationships between biomarkers in aging and dementia. Neurology 73, 1193-1199.
29. Braak, H. and Braak, E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259.
30. Rowe, C.C., Ng, S., Ackermann, U., Gong, S.J., Pike, K., Savage, G., Cowie, T.F., Dickinson, K.L., Maruff, P., Darby, D., Smith, C., Woodward, M., Merory, J., Tochon-Danguy, H., O'Keefe, G., Klunk, W.E., Mathis, C.A., Price, J.C., Masters, C.L. and Villemagne, V.L. (2007) Imaging betaamyloid burden in aging and dementia. Neurology 68, 1718-1725.
31. Rembach, A., Watt, A.D., Wilson, W.J., Villemagne, V.L., Burnham, S.C., Ellis, K.A., Maruff, P., Ames, D., Rowe, C.C., Macaulay, S.L., Bush, A.I., Martins, R.N., Masters, C.L., Doecke, J.D. and Group, A.R. (2014) Plasma amyloid-O levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. J. Alzheimers Dis. 40, 95-104.
32. Wang, T., Xiao, S., Liu, Y., Lin, Z., Su, N., Li, X., Li, G., Zhang, M. and Fang, Y. (2014) The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease. Int. J. Geriatr. Psychiatry 29, 713-719.
33. Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V.M., Trojanowski, J.Q. and Initiative, A. s. D. N. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403-413.
34. Kuo, Y.M., Emmerling, M.R., Lampert, H.C., Hempelman, S.R., Kokjohn, T.A., Woods, A.S., Cotter, R.J. and Roher, A.E. (1999) High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 257, 787-791.
35. Mehta, P.D., Pirttilä, T., Mehta, S.P., Sersen, E.A., Aisen, P.S. and Wisniewski, H.M. (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57, 100-105.
36. Rowe, C.C., Ellis, K.A., Rimajova, M., Bourgeat, P., Pike, K.E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., Price, R., Raniga, P., Robins, P., Acosta, O., Lenzo, N., Szoeke, C., Salvado, O., Head, R., Martins, R., Masters, C.L., Ames, D. and Villemagne, V.L. (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31, 1275-1283.
37. Landau, S.M., Mintun, M.A., Joshi, A.D., Koeppe, R.A., Petersen, R.C., Aisen, P.S., Weiner, M.W., Jagust, W.J. and Initiative, A. s. D. N. (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 72, 578-586.